Inovio Pharmaceuticals Inc（INO）股票分析INOInovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Inovio Pharmaceuticals is not a good buy right now due to its current price of $0.8971, which is significantly below the analyst price target of $3 set by Jefferies. Additionally, the stock has experienced a year-to-date decline of 46.92% and a 5-day change of -9.39%. The RSI of 38.542 indicates that the stock is nearing oversold territory, but the overall trend remains negative. The main risk is the company's ongoing financial struggles, with a net income loss of -6012458.00 USD in Q2 2026, which raises concerns about its long-term viability and ability to recover.

6 analysts cover INO: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 7.33.